Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN

NCT04572854 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04572854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04572854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN
Lead sponsor
Apellis Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 7, 2021
Completion date
January 20, 2026
Enrollment
13 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

c3 glomerulonephritis, c3 glomerulopathy, c3g, complement 3 glomerulonephritis, complement 3 glomerulopathy, complement 3 glomerulopathy (c3g), dense deposit disease (ddd), ic-mpgn, immune complex membranoproliferative glomerulonephritis (ic-mpgn), membranoproliferative glomerulonephritis, membranoproliferative glomerulonephritis (mpgn), renal transplant